New pharmacokinetic and pharmacodynamic tools for interferon-alpha (IFN-α) treatment of human cancer

Pierosandro Tagliaferri, Michele Caraglia, Alfredo Budillon, Monica Marra, Giovanni Vitale, Caterina Viscomi, Serena Masciari, Pierfrancesco Tassone, Alberto Abbruzzese, Salvatore Venuta

Research output: Contribution to journalArticle

70 Citations (Scopus)

Abstract

Interferon α (IFN-α) has been widely used in the treatment of human solid and haematologic malignancies. Although the antitumour activity of IFN-α is well recognised at present, no major advances have been achieved in the last few years. Recent findings have provided new information on the molecular mechanisms of the antitumour activity of the cytokine. In fact, IFN-α appears to block cell proliferation, at least in part, through the induction of apoptotic effects. This cytokine can also regulate the progression of tumour cells through the different phases of the cell cycle inducing an increase of the expression of the cyclin-dependent kinase inhibitors p21 and p27. However, it must be considered that IFN-α is a physiologic molecule with ubiquitously expressed receptors that is likely to activate survival mechanisms in the cell. We have recently identified an epidermal growth factor (EGF) Ras-dependent protective response to the apoptosis induced by IFN-α in epidermoid cancer cells. The identification of tissue- and/ or tumour-specific survival pathways and their selective targeting might provide a new approach to improve the efficacy of IFN-α - based treatment of human cancer. Moreover, new pegylated species of IFN-α are now available with a more favourable pharmacokinetic profile. We will review these achievements, and we will specifically address the topic of IFN-α - based molecularly targeted combinatory antitumour approaches.

Original languageEnglish
Pages (from-to)1-10
Number of pages10
JournalCancer Immunology, Immunotherapy
Volume54
Issue number1
DOIs
Publication statusPublished - Jan 2005

Fingerprint

Interferon-alpha
Pharmacokinetics
Neoplasms
Cyclin-Dependent Kinase Inhibitor p21
Cyclin-Dependent Kinase Inhibitor p27
Cytokines
Survival
Hematologic Neoplasms
Epidermal Growth Factor
Interferons
Cell Cycle
Cell Proliferation
Apoptosis

Keywords

  • Combinatory treatment
  • Interferon α
  • Pegylated species
  • Survival pathways

ASJC Scopus subject areas

  • Cancer Research
  • Immunology
  • Oncology

Cite this

New pharmacokinetic and pharmacodynamic tools for interferon-alpha (IFN-α) treatment of human cancer. / Tagliaferri, Pierosandro; Caraglia, Michele; Budillon, Alfredo; Marra, Monica; Vitale, Giovanni; Viscomi, Caterina; Masciari, Serena; Tassone, Pierfrancesco; Abbruzzese, Alberto; Venuta, Salvatore.

In: Cancer Immunology, Immunotherapy, Vol. 54, No. 1, 01.2005, p. 1-10.

Research output: Contribution to journalArticle

Tagliaferri, P, Caraglia, M, Budillon, A, Marra, M, Vitale, G, Viscomi, C, Masciari, S, Tassone, P, Abbruzzese, A & Venuta, S 2005, 'New pharmacokinetic and pharmacodynamic tools for interferon-alpha (IFN-α) treatment of human cancer', Cancer Immunology, Immunotherapy, vol. 54, no. 1, pp. 1-10. https://doi.org/10.1007/s00262-004-0549-1
Tagliaferri, Pierosandro ; Caraglia, Michele ; Budillon, Alfredo ; Marra, Monica ; Vitale, Giovanni ; Viscomi, Caterina ; Masciari, Serena ; Tassone, Pierfrancesco ; Abbruzzese, Alberto ; Venuta, Salvatore. / New pharmacokinetic and pharmacodynamic tools for interferon-alpha (IFN-α) treatment of human cancer. In: Cancer Immunology, Immunotherapy. 2005 ; Vol. 54, No. 1. pp. 1-10.
@article{f8e486a68dd3443990b73262f558c8a7,
title = "New pharmacokinetic and pharmacodynamic tools for interferon-alpha (IFN-α) treatment of human cancer",
abstract = "Interferon α (IFN-α) has been widely used in the treatment of human solid and haematologic malignancies. Although the antitumour activity of IFN-α is well recognised at present, no major advances have been achieved in the last few years. Recent findings have provided new information on the molecular mechanisms of the antitumour activity of the cytokine. In fact, IFN-α appears to block cell proliferation, at least in part, through the induction of apoptotic effects. This cytokine can also regulate the progression of tumour cells through the different phases of the cell cycle inducing an increase of the expression of the cyclin-dependent kinase inhibitors p21 and p27. However, it must be considered that IFN-α is a physiologic molecule with ubiquitously expressed receptors that is likely to activate survival mechanisms in the cell. We have recently identified an epidermal growth factor (EGF) Ras-dependent protective response to the apoptosis induced by IFN-α in epidermoid cancer cells. The identification of tissue- and/ or tumour-specific survival pathways and their selective targeting might provide a new approach to improve the efficacy of IFN-α - based treatment of human cancer. Moreover, new pegylated species of IFN-α are now available with a more favourable pharmacokinetic profile. We will review these achievements, and we will specifically address the topic of IFN-α - based molecularly targeted combinatory antitumour approaches.",
keywords = "Combinatory treatment, Interferon α, Pegylated species, Survival pathways",
author = "Pierosandro Tagliaferri and Michele Caraglia and Alfredo Budillon and Monica Marra and Giovanni Vitale and Caterina Viscomi and Serena Masciari and Pierfrancesco Tassone and Alberto Abbruzzese and Salvatore Venuta",
year = "2005",
month = "1",
doi = "10.1007/s00262-004-0549-1",
language = "English",
volume = "54",
pages = "1--10",
journal = "Cancer Immunology and Immunotherapy",
issn = "0340-7004",
publisher = "Springer Science and Business Media Deutschland GmbH",
number = "1",

}

TY - JOUR

T1 - New pharmacokinetic and pharmacodynamic tools for interferon-alpha (IFN-α) treatment of human cancer

AU - Tagliaferri, Pierosandro

AU - Caraglia, Michele

AU - Budillon, Alfredo

AU - Marra, Monica

AU - Vitale, Giovanni

AU - Viscomi, Caterina

AU - Masciari, Serena

AU - Tassone, Pierfrancesco

AU - Abbruzzese, Alberto

AU - Venuta, Salvatore

PY - 2005/1

Y1 - 2005/1

N2 - Interferon α (IFN-α) has been widely used in the treatment of human solid and haematologic malignancies. Although the antitumour activity of IFN-α is well recognised at present, no major advances have been achieved in the last few years. Recent findings have provided new information on the molecular mechanisms of the antitumour activity of the cytokine. In fact, IFN-α appears to block cell proliferation, at least in part, through the induction of apoptotic effects. This cytokine can also regulate the progression of tumour cells through the different phases of the cell cycle inducing an increase of the expression of the cyclin-dependent kinase inhibitors p21 and p27. However, it must be considered that IFN-α is a physiologic molecule with ubiquitously expressed receptors that is likely to activate survival mechanisms in the cell. We have recently identified an epidermal growth factor (EGF) Ras-dependent protective response to the apoptosis induced by IFN-α in epidermoid cancer cells. The identification of tissue- and/ or tumour-specific survival pathways and their selective targeting might provide a new approach to improve the efficacy of IFN-α - based treatment of human cancer. Moreover, new pegylated species of IFN-α are now available with a more favourable pharmacokinetic profile. We will review these achievements, and we will specifically address the topic of IFN-α - based molecularly targeted combinatory antitumour approaches.

AB - Interferon α (IFN-α) has been widely used in the treatment of human solid and haematologic malignancies. Although the antitumour activity of IFN-α is well recognised at present, no major advances have been achieved in the last few years. Recent findings have provided new information on the molecular mechanisms of the antitumour activity of the cytokine. In fact, IFN-α appears to block cell proliferation, at least in part, through the induction of apoptotic effects. This cytokine can also regulate the progression of tumour cells through the different phases of the cell cycle inducing an increase of the expression of the cyclin-dependent kinase inhibitors p21 and p27. However, it must be considered that IFN-α is a physiologic molecule with ubiquitously expressed receptors that is likely to activate survival mechanisms in the cell. We have recently identified an epidermal growth factor (EGF) Ras-dependent protective response to the apoptosis induced by IFN-α in epidermoid cancer cells. The identification of tissue- and/ or tumour-specific survival pathways and their selective targeting might provide a new approach to improve the efficacy of IFN-α - based treatment of human cancer. Moreover, new pegylated species of IFN-α are now available with a more favourable pharmacokinetic profile. We will review these achievements, and we will specifically address the topic of IFN-α - based molecularly targeted combinatory antitumour approaches.

KW - Combinatory treatment

KW - Interferon α

KW - Pegylated species

KW - Survival pathways

UR - http://www.scopus.com/inward/record.url?scp=19944429258&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=19944429258&partnerID=8YFLogxK

U2 - 10.1007/s00262-004-0549-1

DO - 10.1007/s00262-004-0549-1

M3 - Article

VL - 54

SP - 1

EP - 10

JO - Cancer Immunology and Immunotherapy

JF - Cancer Immunology and Immunotherapy

SN - 0340-7004

IS - 1

ER -